ArticleJournal of cardiothoracic surgery2026
Attenuation of sepsis-associated acute lung injury by lncRNA LINC00052 via sponging miR-106b-5p.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis-associated acute lung injury (SA-ALI) is a prevalent sequela of sepsis, which imposes a substantial public health burden. Due to the incomplete understanding of its underlying pathogenesis, no fundamental breakthroughs in its treatment have been achieved. To explore the predictive value of LINC00052 and miR-106b-5p in SA-ALI and clarify its mechanism.
methodsLINC00052 and miR-106b-5p levels were quantified using real-time quantitative polymerase chain reaction (RT-qPCR). The predictive capacity for SA-ALI was assessed using receiver operating characteristic (ROC) curve analysis. Risk factors associated with ALI development were evaluated by Logistic regression. Pearson analysis was conducted to examine the correlation between LINC00052 and clinical indicators. Cellular viability was determined via cell counting kit-8 (CCK-8) assay and flow cytometry, while the concentrations of inflammatory and apoptotic factors were measured using enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB).
resultsLINC00052 levels in serum from sepsis patients were lower than in the healthy group and further decreased with the development of SA-ALI, whereas miR-106b-5p expression showed the opposite trend. LINC00052 and miR-106b-5p demonstrated high diagnostic value in distinguishing ALI patients, with enhanced predictive efficacy when combined. LINC00052 expression was inversely correlated with clinical indicators in SA-ALI patients. Mechanistically, upregulation of LINC00052 modulated proliferation, apoptosis, inflammation, and apoptosis markers in A549 cells, an effect cancelled by miR-106b-5p mimic.
conclusionsLINC00052 functions by sponging miR-106b-5p to suppress apoptosis and mitigate inflammation, with the LINC00052/miR-106b-5p axis exhibits excellent predictive value for SA-ALI, underscoring their clinical relevance as both therapeutic targets and diagnostic biomarkers.
Indexed as
Identifiers
42363260What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.